Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of Tuesday, October 6, 2026.
RETURN ON ASSETS (ROA)
N/A
Market Cap
$227.60M
Return on Assets (ROA)
-29.12%
TTM Avg
-42.23%
3Y Avg
-51.88%
5Y Avg
-48.35%
Market Cap
$225.24M
Return on Assets (ROA)
-34.55%
TTM Avg
-30.02%
3Y Avg
-24.36%
5Y Avg
-21.40%
Market Cap
$231.37M
Return on Assets (ROA)
-4.22%
TTM Avg
-27.32%
3Y Avg
-24.76%
5Y Avg
-32.27%
Market Cap
$231.77M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
Market Cap
$232.72M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
Market Cap
$220.93M
Return on Assets (ROA)
-52.33%
TTM Avg
-30.08%
3Y Avg
-42.41%
5Y Avg
-37.62%
Market Cap
$235.08M
Return on Assets (ROA)
8.42%
TTM Avg
10.27%
3Y Avg
11.53%
5Y Avg
11.43%
Market Cap
$235.66M
Return on Assets (ROA)
-8.48%
TTM Avg
-16.43%
3Y Avg
-20.20%
5Y Avg
-32.31%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vogenx Inc. (VOGX) | $227.91M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | -29.12% | -42.23% | -51.88% | -48.35% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | -34.55% | -30.02% | -24.36% | -21.40% |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | -4.22% | -27.32% | -24.76% | -32.27% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | -244.25% | -369.36% | -230.97% | -157.86% |
| InflaRx N.V. (IFRX)vs › | $232.72M | -23.88% | -71.64% | -51.89% | -47.09% |
| Profound Medical Corp. (PROF)vs › | $220.93M | -52.33% | -30.08% | -42.41% | -37.62% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 8.42% | 10.27% | 11.53% | 11.43% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | -8.48% | -16.43% | -20.20% | -32.31% |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | -1.57% | 17.43% | 19.75% | 24.82% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
